-
Use of a "fuzzy logic" controller in a closed-loop artificial pancreas.
Diabetes Technology & TherapeuticsMauseth R, Hirsch IB, Bollyky J, Kircher R, Matheson D, Sanda S, Greenbaum CJ -
Response to Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012;61:2066-2073.
DiabetesGreenbaum CJ, Beam CA, Type 1 Diabetes TrialNet Study Group. -
Immunological biomarkers: catalysts for translational advances in autoimmune diabetes.
Clinical and Experimental ImmunologyAhmed ST, Akirav E, Bradshaw E, Buckner JH, McKinney E, Quintana FJ, Waldron-Lynch F, Nepom GT -
CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring.
ImmunologyYang J, James EA, Sanda S, Greenbaum CJ, Kwok WW -
The influence of exposure to maternal diabetes in utero on the rate of decline in β-cell function among youth with diabetes.
Journal of Pediatric Endocrinology & MetabolismCrume TL, Andrews JS, D'Agostino RB Jr, Pettitt DJ, Mayer-Davis EJ, Law JR, Dolan L, Lawrence JM, Saydah S, Greenbaum CJ, Rodriguez BL, Dabelea DM, SEARCH for Diabetes in Youth Study Group. -
Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study.
DiabetologiaDabelea D, Mayer-Davis EJ, Andrews JS, Dolan LM, Pihoker C, Hamman RF, Greenbaum CJ, Marcovina SM, Fujimoto W, Linder B, Imperatore G, D'Agostino R Jr -
Improvement in outcomes of clinical islet transplantation: 1999-2010.
Diabetes CareBarton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, Pattou F, Berney T, Secchi A, Messinger S, Senior PA, Maffi P, Posselt A, Stock PG, Kaufman DB, Luo X, Kandeel F, Cagliero E, Turgeon NA, Witkowski P, Naji A, O'Connell PJ, Greenbaum CJ, Kudva YC, Brayman KL, Aull MJ, Larsen C, Kay TWH, Fernandez LA, Vantyghem MC, Bellin MD, Shapiro AMJ -
Perspective: Rethink the immune connection.
NatureGreenbaum CJ -
Dead or alive?
Diabetes CareGreenbaum CJ -
Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience.
The Review of Diabetic StudiesEhlers MR, Nepom GT -
Effect of rituximab on human in vivo antibody immune responses.
The Journal of Allergy and Clinical ImmunologyPescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum CJ, Herold KC, Skyler JS, Weinberg A, Type 1 Diabetes TrialNet Study Group. -
Making progress: preserving beta cells in type 1 diabetes.
Annals of the New York Academy of SciencesGallagher MP, Goland RS, Greenbaum CJ -
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
LancetOrban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group. -
Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363.
DiabetesSanda S, Greenbaum CJ -
Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes.
DiabetesGreenbaum CJ, Atkinson MA
